January 30 Jan 30
Saturday Sat

Stanford Hematology Review of the 57th Annual ASH Meeting

The Ritz-Carlton - Half Moon Bay, CA

A Continuing Medical Education Conference

Presented by the Division of Hematology at Stanford University School of Medicine

Sponsored by the Stanford University School of Medicine

Conference Contact

Assistant Director, Development Events, Office of Development

Mailing List

New activities are added regularly.  Join our mailing list to receive notifications about activities of interest to you.

Learning Objectives

At the conclusion of this activity, participants should be able to review and evaluate data from the most recent clinical trials and develop strategies to:

• Evaluate new chemotherapy/biologic regimens for different subpopulations of acute myeloid leukemia patients based on clinical and genetic prognostic factors and determine how to apply them to treatment decisions

• Apply strategies to optimally utilize JAK inhibition and other novel agents in patients with myelofibrosis, PV, and other relevant MPNs and use prognostic models to risk stratify MPN patients for therapy

• Determine best practice for using biologic agents with or without chemotherapy as initial therapy or for relapsed/refractory chronic lymphocytic leukemia

• Determine available therapeutic options for patients with low- or high-risk myelodysplastic syndromes, including those who are relapsed/refractory to hypomethylating agents and utilize the IPSS-R prognostic scoring system and new mutation data to classify patients for treatment

• Identify best combination regimens and novel agents for relevant populations of myeloma patients, including transplant eligible vs. ineligible, and new antibody therapies

• Evaluate differences in indications, dose, and safe use of oral anticoagulants and assess new long acting drugs for hemophilia

• Implement BTK and PI3K inhibition, anti-CD30 antibody drug immunoconjugate therapy and other agents for the treatment of chronic lymphocytic leukemia and/or lymphomas, either alone or in combination with conventional therapies

• Incorporate new data for optimizing treatment of iron overload/ deficiency into practice and analyze the biologic pathways relevant to iron homeostasis, including inflammatory states; evaluate novel preclinical and clinical data related to hemoglobinopathies